Efficacy News and Research

RSS

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

11 Oct 2011

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

DNA vaccine development company Coridon Pty Ltd. today announced that it had successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with outstanding results. The company will now look to progress the program into clinical studies.

10 Oct 2011

Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer's disease. The study is the subject of a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration.

10 Oct 2011

AIT Laboratories introduces new suite of services for prescription compliance monitoring

Chronic pain affects an estimated 116 million adults in the U.S.—more than the number affected by heart disease, diabetes, and cancer combined, according to a recent report by the Institute of Medicine.

10 Oct 2011

Unither Virology receives NIAID contract for glycobiology antiviral platform

United Therapeutics Corporation announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.

10 Oct 2011

Researchers focus on gelatinase inhibitor compounds to treat neurological diseases

Results of a study by a group of University of Notre Dame researchers represent a promising step on the road to developing new drugs for a variety of neurological diseases.

10 Oct 2011

New $13.75M data-mining project to better understand factors behind mental disorders

Chicago will be home to a new $13.75 million project that will apply data mining methods to better understand the genetic and environmental factors behind neuropsychiatric disorders.

7 Oct 2011

Virginia Bioinformatics Institute releases upgraded ENISI software

Researchers with the Virginia Bioinformatics Institute at Virginia Tech have released an upgrade to the institute's ENteric Immunity SImulator (ENISI) software, which models immune responses to beneficial and harmful bacteria that enter the gastrointestinal tract of mice, pigs, and humans.

7 Oct 2011

Dramatic rise in U.S. incidence of oropharyngeal cancer can be attributed to HPV infection

A new study of oropharyngeal cancer suggests that dramatic increases in U.S. incidence of the cancer and survival since 1984 can be attributed to infection with the human papillomavirus.

4 Oct 2011

Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH

The first patient has now been included in Karo Bio's phase III trial with eprotirome. A total of 630 patients with the hereditary condition HeFH will be studied for safety, and to confirm the beneficial effects on LDL-cholesterol that has been shown previously.

4 Oct 2011

New review explores how nanotechnology may develop safer breast implants

A new review published in WIREs Nanomedicine and Nanobiotechnology explores how nanotechnology may be used to develop safer breast implants as an alternative to silicone rubber, minimizing health complications.

4 Oct 2011

Three Penn labs receive NIH grant to speed translation of medical research into patient care

Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.

4 Oct 2011

Phagenesis closes Series B funding

Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.

4 Oct 2011

Creabilis receives $20 million in Series B funding

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.

4 Oct 2011

MR-guided focused ultrasound may effectively control essential tremor

In a presentation at the Congress of Neurological Surgeons today, University of Virginia neurosurgeon W. Jeffrey Elias, MD reported that preliminary results of a pilot clinical trial indicate that MR-guided focused ultrasound has the potential to safely and effectively control essential tremor (ET), a common neurological condition that affects 10 million Americans.

4 Oct 2011

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

AMRI announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla.

4 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first patients have been dosed in the Company's phase IIIb trial of XIAFLEX® for the treatment of adult Dupuytren's contracture patients with multiple palpable cords.

3 Oct 2011

Efficacy News and Research

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease

AIT Laboratories introduces new suite of services for prescription compliance monitoring

Unither Virology receives NIAID contract for glycobiology antiviral platform

Researchers focus on gelatinase inhibitor compounds to treat neurological diseases

New $13.75M data-mining project to better understand factors behind mental disorders

Virginia Bioinformatics Institute releases upgraded ENISI software

Dramatic rise in U.S. incidence of oropharyngeal cancer can be attributed to HPV infection

Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH

New review explores how nanotechnology may develop safer breast implants

Three Penn labs receive NIH grant to speed translation of medical research into patient care

Phagenesis closes Series B funding

Creabilis receives $20 million in Series B funding

MR-guided focused ultrasound may effectively control essential tremor

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

Adaptimmune announces new board appointments as clinical programmes get underway

Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News